Nuvilex, Inc. Reports that Phase 2 Microplot Trials of Oraphyte Confirm it To Be a Commercially Viable All-Natural Nematocide

Friday, October 23, 2009 General News
Email Print This Page Comment bookmark
Font : A-A+

CHERRY HILL, N.J., Oct. 22 Nuvilex, Inc. (OTC Bulletin Board: NVLX) announced today that it has received the final report from its Phase 2 microplot trials investigating the use of Oraphyte(TM) as an all-natural, eco-friendly nematocide for the turfgrass market with results supporting the commercial viability of the product. Over the past three years, nematologist and plant pathologist Edward McGawley, Ph.D. of the Louisiana State University's Agricultural Center (LSU AgCenter) has investigated the use of Oraphyte(TM) on several species of turfgrass, including St. Augustine turfgrass (Stenotaphrum secundatum), bermudagrass (Cynodon dactylon), and creeping bentgrass (Agrostis).

During the summer of 2009, Dr. McGawley and his team of researchers applied Oraphyte(TM) to the soil of microplots that contained bermudagrass and creeping bentgrass. The primary goals of the Phase 2 microplot trials were to determine if Oraphyte(TM) could substantially reduce the populations of six nematode genera while causing minimal damage to the blades and root structures of turfgrass. Results from the Phase 2 microplot trials indicate that one treatment of 7% Oraphyte(TM) is able to reduce the nematode population while causing little or no damage to the blades and root structures of turfgrass. Further turf studies with Oraphyte(TM) are underway in a recreational golf environment.

"With these results in hand, we are able to work toward finalizing our ongoing discussions with a Fortune 100 company, as well as other private companies operating in the pesticide industry that have expressed an interest in licensing the Oraphyte(TM) product for other crop-related uses," stated Martin Schmieg, Chairman and Chief Executive Officer of Nuvilex, Inc. "Our objective is to establish a long-term licensing agreement for the marketing and sale of Oraphyte(TM), and with every favorable test result we receive, we move closer to making this goal a reality."

About Oraphyte(TM)

Oraphyte(TM) is a biodegradable nematocide for turfgrass and high-value crops that is derived from plants and other naturally occurring substances. Oraphyte(TM) can be formulated as a liquid or solid and is composed of orange terpene oil, Valencia orange oil, hydrogen peroxide, sorbitan monooleate, and distilled water. All of Oraphyte(TM)'s ingredients are listed on the Office of Prevention, Pesticides, and Toxic Substances (OPPTS) of the EPA's inert ingredient list. Such a designation indicates that these ingredients pose minimal risk to the environment.

From 2007 to 2009, Oraphyte(TM) has undergone testing at LSU, Auburn University, the University of Florida, Ohio State University, and the United States Department of Agriculture (USDA) to determine its efficacy and usefulness as a non-toxic, low-cost alternative to many traditional nematocides, including Nemacur, Curfew, Telone II, and Temik. In addition to turfgrass, Oraphyte(TM) has been tested on several high value crops, including cantaloupes, tomatoes, and cucumbers.

About Nuvilex, Inc.

Nuvilex, Inc. is an emerging healthcare consumer products company. The Company's lead products include: Last Shot Hangover Remedy(TM), a unique sugar-free, calorie-free and caffeine-free liquid formula designed to ease the symptoms of a hangover; Cinnergen(TM), which promotes a healthy glucose metabolism; Cinnechol(TM), designed to help maintain normal cholesterol levels and support normal cardiovascular function; and Infinitink®, a permanent yet more easily removable tattoo ink. The Company's complete portfolio spans aesthetics, dermatology, environmental and nutraceutical products, all of which are designed to directly or indirectly improve human health. In March 2009, Nuvilex merged with Freedom2 Holdings, Inc., the developer of Infinitink®. In conjunction with the merger, the Company changed its name to Nuvilex, Inc. from Please visit for additional information on the Company.

Safe Harbor Statement

Statements contained in this press release that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Forward-looking statements are sometimes identified by words such as "intends", "anticipates", "believes", "expects", and "hopes" and involve a number of risks and uncertainties that could cause the Company's actual results to differ materially from projected results. All parties are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, the Company's ability to secure additional financing, and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.

Company Contact: Blair Barnes Senior Vice President and Chief Financial Officer Nuvilex, Inc. Ph: 856-433-6088 Email: Press Contact: Pat Arcand Arcand & Madison Ph: 617-576-7777 Email:

SOURCE Nuvilex, Inc.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store